What the research found

A clinical trial compared three diet patterns—ketogenic, Mediterranean, and low-fat—in people with obesity, prediabetes, and non-alcoholic fatty liver disease. All three diets produced similar weight loss (around 10% of body weight), suggesting that adherence and caloric deficit matter across approaches. However, the ketogenic group showed substantially greater reduction in liver fat accumulation relative to the other two groups, and roughly half of keto participants no longer met diagnostic criteria for prediabetes after four to five months of the intervention.

The trial ran for approximately four to five months, long enough to detect metabolic shifts but short enough that we don't know about durability or longer-term safety.

Why it matters for you

If you're tracking liver health markers (AST, ALT, GGT) or monitoring fasting glucose and insulin sensitivity, this is relevant data. Many MyKine users with elevated liver enzymes or insulin resistance consider keto as a potential intervention. The finding suggests that if your primary goal is reducing hepatic fat—which often correlates with improved liver enzyme profiles and insulin sensitivity—keto may work more directly than equivalent weight loss alone on a different macronutrient split.

The prediabetes reversal rate is noteworthy for users tracking fasting glucose, HbA1c, or glucose tolerance. However, the trial doesn't specify whether improvements came from weight loss alone or from metabolic changes unique to ketosis. This matters when deciding whether to adopt keto strictly or whether a caloric deficit on another diet could work as well for you personally.

Caveats

• Short duration: Four to five months tells us about acute metabolic response, not whether benefits persist or adverse effects emerge over years
• No mechanistic detail: The source doesn't clarify whether liver fat reduction came from weight loss itself or from ketone-specific hepatic effects
• No individual variation data: We don't know who responded best or worst, or whether certain biomarker baselines predicted success
• Missing adherence metrics: Equal weight loss across groups suggests good compliance overall, but dropout rates and subjective tolerability aren't reported